Fabrice Viviani

USPTO Granted Patents = 22 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 2)

Average Co-Inventor Count = 7.9

ph-index = 7

Forward Citations = 155(Granted Patents)

Location History:

Louvre, FR (2007)
Louvres, FR (2002 - 2011)
Avenheim, FR (2011)
Paris, FR (2014 - 2015)

Company Filing History:

Sanofi-a Ventis Deutschland Gmbh

patents

Years Active: 2002-2015

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9120812 - Pyrimidooxazocine derivatives as mTOR-inhibitors (2015-09-01),

2. 8846670 - 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof, and pharmaceutical use thereof (2014-09-30),

3. 8846654 - Therapeutic applications in the cardiovascular field of quinazolinedione derivatives (2014-09-30),

4. 8828997 - 2,3-dihydro-1H-imidazo(1,2-a)pyrimidin-5-one derivatives, preparation thereof, and pharmaceutical use thereof (2014-09-09),

5. 8748441 - Therapeutic uses of quinazolinedione derivatives (2014-06-10),

6. 8058290 - 7-substituted aza-indazoles, compositions containing same, production method and use thereof (2011-11-15),

7. 8008322 - Substituted pyrazolopyridines, compositions containing them, method for the production thereof, and their use (2011-08-30),

8. 7947706 - Substituted pyrrolopyridines, compositions containing them, manufacturing process therefor and use thereof (2011-05-24),

9. 7592365 - Substituted pyrroles, compositions containing same, method for making same and use thereof (2009-09-22),

10. 7566736 - Substituted indoles, compositions containing them, method for the production thereof and their use (2009-07-28),

11. 7560571 - Substituted pyrroles and imidazoles, compositions containing same, manufacturing process therefor and use thereof (2009-07-14),

12. 7517902 - Substituted indazoles, compositions containing the same, and the preparation and use thereof (2009-04-14),

13. 7435820 - [object Object] (2008-10-14),

14. 7232834 - Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor (2007-06-19),

15. 7232833 - 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them (2007-06-19),

Title: Innovations and Contributions of Fabrice Viviani

Introduction

Fabrice Viviani, an esteemed inventor based in Louvres, France, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 22 patents. His inventive work primarily focuses on the development of innovative therapeutic compounds aimed at addressing critical health issues.

Latest Patents

Among his latest patents, Fabrice has developed pyrimidooxazocine derivatives recognized as mTOR-inhibitors. This invention pertains to bicyclic heterocyclic derivatives outlined in general formula (I), which are pivotal for creating new therapeutic strategies. Additionally, he holds a patent for the therapeutic applications of quinazolinedione derivatives, focusing on their use as medicaments for treating and preventing cardiovascular diseases.

Career Highlights

Fabrice Viviani's career is marked by his tenure at prominent pharmaceutical companies such as Aventis Pharma and Sanofi, where he has employed his expertise to drive forward innovative healthcare solutions. His contributions in these significant institutions have reinforced their commitment to advancing medical treatments.

Collaborations

Throughout his career, Fabrice has collaborated with distinguished professionals including Michel Tabart and Baptiste Ronan. These collaborative efforts have facilitated the development of groundbreaking inventions, enhancing both research outcomes and therapeutic applications.

Conclusion

Fabrice Viviani's work exemplifies a profound dedication to innovation in pharmaceuticals. His patents not only highlight his creativity and scientific acumen but also illustrate his commitment to improving health outcomes through new therapeutic compounds. With a robust foundation and continued collaboration, he remains a key figure in the advancement of medical science.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

1 patent pending:

Please report any incorrect information to support@idiyas.com

8 patents (EPO):

Please report any incorrect information to support@idiyas.com

2 patents pending (EPO):

Please report any incorrect information to support@idiyas.com